Summary by Moomoo AI
Sino Biopharm Limited ("the Company") announced its unaudited interim results for the six months ended June 30, 2024. During the period, the Company's revenue reached RMB 15.87 billion, an 11.1% year-on-year increase; the profit attributable to owners of the parent company was RMB 3.02 billion, a significant 139.7% year-on-year increase. The adjusted basic earnings per share attributable to owners of the parent company, calculated based on non-Hong Kong Financial Reporting Standards, was RMB 8.34, a 15.0% year-on-year increase. The Board of Directors of the Company declared an interim dividend of 3 Hong Kong cents per share for the six months ended June 30, 2024. The Company is incorporated in the Cayman Islands, with main businesses including manufacturing, selling, and distributing modern traditional Chinese medicine formulations and Western medicine products. The Company's shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited.
